Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12444700 | 0.78 | PTPN11 (0.33) | PTPN11 | |
| SCHEMBL18265829 | 0.77 | PTPN11 (0.33) | PTPN11 | |
| SCHEMBL14645312 | 0.70 | TDP1 (0.31) | — | |
| SCHEMBL3159737 | 0.69 | DAO (0.47) | DAO | |
| SCHEMBL15883339 | 0.65 | BACE1 (0.38) | PTPN11 | |
| SCHEMBL13879198 | 0.65 | GRM5 (0.44) | PTPN11 | |
| SCHEMBL18677558 | 0.64 | FFAR1 (0.43) | — | |
| SCHEMBL15957593 | 0.62 | L3MBTL1 (0.42) | PTPN11 | |
| SCHEMBL280067 | 0.62 | ESR1 (0.40) | DAO | |
| SCHEMBL9694697 | 0.61 | GRM5 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045462-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8927741-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140275570-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8759544-B2 | Synthesis of an antiviral compound | GILEAD SCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140051866-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051867-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275570-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, SARS1, MAVS | DAO 738/4885PTPN11 3995/4885 |
| US-20140051867-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, SARS1, MAVS | DAO 738/4885PTPN11 3995/4885 |
| US-20140051866-A1 | SYNTHESIS OF AN ANTIVIRAL COMPOUND | EIF2AK2, SARS1, MAVS | DAO 744/4885PTPN11 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.